Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.7 ILa | +23.33% |
|
+27.59% | +42.31% |
06-10 | Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study | CI |
06-06 | Transcript : Can-Fite BioPharma Ltd. - Special Call |